BR112012008951A2 - tratamento de neurotoxidez associada com combinações de 5-fu ou seus profármacos e inibidores de dpd - Google Patents
tratamento de neurotoxidez associada com combinações de 5-fu ou seus profármacos e inibidores de dpdInfo
- Publication number
- BR112012008951A2 BR112012008951A2 BR112012008951A BR112012008951A BR112012008951A2 BR 112012008951 A2 BR112012008951 A2 BR 112012008951A2 BR 112012008951 A BR112012008951 A BR 112012008951A BR 112012008951 A BR112012008951 A BR 112012008951A BR 112012008951 A2 BR112012008951 A2 BR 112012008951A2
- Authority
- BR
- Brazil
- Prior art keywords
- prodrugs
- dpd
- combinations
- treatment
- patient
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
tratamento de neurotoxidez associada com combinações de 5-fu ou seus profármacos e inibidores de dpd a presente invenção refere-se a processos para aperfeiçoada administração e dosagem de inibidores de dpd em combinção coom 5-fu e/ou profármacos de 5-fu, compreendendo primeiro a administração a um paciente em suas necessidade de um inibidor de dpd que elimina substancialmente atividade da enzima em ambos tecidos nervosos e não nervosos dentro do paciente e a seguir admionistração 5-fu ou um profármaco de 5-fu em que o nível de 5-fu ou 5-fu gerada de um profármaco está em excesso substancial de inidor de dpd no paciente.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25144909P | 2009-10-14 | 2009-10-14 | |
PCT/US2010/052734 WO2011047195A1 (en) | 2009-10-14 | 2010-10-14 | Treating neurotoxicity associated with combinations of 5 - fu or its prodrugs and dpd inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112012008951A2 true BR112012008951A2 (pt) | 2019-09-24 |
Family
ID=43466528
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112012008951A BR112012008951A2 (pt) | 2009-10-14 | 2010-10-14 | tratamento de neurotoxidez associada com combinações de 5-fu ou seus profármacos e inibidores de dpd |
Country Status (14)
Country | Link |
---|---|
US (1) | US8658618B2 (pt) |
EP (1) | EP2488182B1 (pt) |
JP (2) | JP2013508293A (pt) |
KR (1) | KR20120127709A (pt) |
CN (1) | CN102811721A (pt) |
AU (1) | AU2010306698B2 (pt) |
BR (1) | BR112012008951A2 (pt) |
CA (1) | CA2777546C (pt) |
CO (1) | CO6541596A2 (pt) |
EA (1) | EA201270551A1 (pt) |
ES (1) | ES2644237T3 (pt) |
IL (1) | IL219179A0 (pt) |
MX (1) | MX2012004383A (pt) |
WO (1) | WO2011047195A1 (pt) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014089004A1 (en) * | 2012-12-04 | 2014-06-12 | Adherex Technologies, Inc. | Methods for treating 5-fluorouracil prodrug non-responsive cancer patients |
CN106692173A (zh) * | 2015-11-18 | 2017-05-24 | 北京诺普德医药科技有限公司 | 一种抗肿瘤复方组合物及其应用 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5687599A (en) | 1979-12-19 | 1981-07-16 | Yamasa Shoyu Co Ltd | E 55 22halogenovinyl arabinofuranosyluracil and its preparation |
GB8629892D0 (en) | 1986-12-15 | 1987-01-28 | Wellcome Found | Antiviral compounds |
US5157114A (en) | 1988-08-19 | 1992-10-20 | Burroughs Wellcome Co. | 2',3'-dideoxy-3'-fluoro-5-ethyngluridine |
JP3094036B2 (ja) * | 1990-07-19 | 2000-10-03 | ザ ウエルカム ファウンデーション リミテッド | 酵素不活性化剤 |
GB9020930D0 (en) | 1990-09-26 | 1990-11-07 | Wellcome Found | Pharmaceutical combinations |
US5476855A (en) * | 1993-11-02 | 1995-12-19 | Mahmoud H. el Kouni | Enzyme inhibitors, their synthesis and methods for use |
NZ330360A (en) * | 1997-06-02 | 1999-03-29 | Hoffmann La Roche | 5'-deoxy-cytidine derivatives, their manufacture and use as antitumoral agents |
US6716452B1 (en) * | 2000-08-22 | 2004-04-06 | New River Pharmaceuticals Inc. | Active agent delivery systems and methods for protecting and administering active agents |
US20040028687A1 (en) * | 2002-01-15 | 2004-02-12 | Waelti Ernst Rudolf | Methods and compositions for the targeted delivery of therapeutic substances to specific cells and tissues |
MX2007006646A (es) * | 2004-12-03 | 2007-11-16 | Adherex Technologies Inc | Metodos para administrar inhibidores de dihidropirimidina deshidrogenasa en combinacion con 5-fluorouracilo y profarmacos de 5-fluorouracilo. |
-
2010
- 2010-10-14 ES ES10768670.1T patent/ES2644237T3/es active Active
- 2010-10-14 KR KR1020127012289A patent/KR20120127709A/ko not_active Application Discontinuation
- 2010-10-14 WO PCT/US2010/052734 patent/WO2011047195A1/en active Application Filing
- 2010-10-14 MX MX2012004383A patent/MX2012004383A/es not_active Application Discontinuation
- 2010-10-14 CA CA2777546A patent/CA2777546C/en active Active
- 2010-10-14 CN CN2010800562916A patent/CN102811721A/zh active Pending
- 2010-10-14 EA EA201270551A patent/EA201270551A1/ru unknown
- 2010-10-14 JP JP2012534373A patent/JP2013508293A/ja active Pending
- 2010-10-14 BR BR112012008951A patent/BR112012008951A2/pt not_active IP Right Cessation
- 2010-10-14 AU AU2010306698A patent/AU2010306698B2/en active Active
- 2010-10-14 US US12/904,974 patent/US8658618B2/en active Active
- 2010-10-14 EP EP10768670.1A patent/EP2488182B1/en active Active
-
2012
- 2012-04-15 IL IL219179A patent/IL219179A0/en unknown
- 2012-05-14 CO CO12078833A patent/CO6541596A2/es not_active Application Discontinuation
-
2015
- 2015-09-29 JP JP2015190757A patent/JP2016014051A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CN102811721A (zh) | 2012-12-05 |
AU2010306698B2 (en) | 2016-05-26 |
MX2012004383A (es) | 2012-08-23 |
WO2011047195A1 (en) | 2011-04-21 |
CA2777546A1 (en) | 2011-04-21 |
EA201270551A1 (ru) | 2012-12-28 |
ES2644237T3 (es) | 2017-11-28 |
JP2016014051A (ja) | 2016-01-28 |
AU2010306698A1 (en) | 2012-05-17 |
IL219179A0 (en) | 2012-06-28 |
KR20120127709A (ko) | 2012-11-23 |
EP2488182A1 (en) | 2012-08-22 |
CA2777546C (en) | 2019-11-05 |
CO6541596A2 (es) | 2012-10-16 |
JP2013508293A (ja) | 2013-03-07 |
EP2488182B1 (en) | 2017-07-19 |
US8658618B2 (en) | 2014-02-25 |
US20110130359A1 (en) | 2011-06-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12017501500A1 (en) | Methods for treating non- small cell lung cancer using tor kinase inhibitor combination therapy | |
NI200900106A (es) | Inhibidores de la actividad de la akt. | |
GEP20166455B (en) | Methods of administering pirfenidone therapy | |
BR112016014481A2 (pt) | tratamento de câncer utilizando combinações de inibidores de erk e raf | |
EP3447491A3 (en) | Diagnosis and treatments relating to th2 inhibition | |
WO2008147482A3 (en) | Methods and compositions for improving immune responses | |
MX2009012197A (es) | Metodos para tratamiento de ulceras en la piel. | |
MX2012000817A (es) | Tratamiento para desordenes del higado con inhibidores pi3k. | |
MX366774B (es) | Uso de oligonucleótidos antisentido en la inhibición de transcrito antisentido natural para sirtuina 1. | |
BR112013007681A2 (pt) | uso terapêutico de um agonista trl e terapia de combinação | |
EA201491694A1 (ru) | Лечение рака ингибиторами tor киназы | |
NI201400110A (es) | Tratamiento del cáncer con inhibidores tor cinasa | |
MX2015014599A (es) | Terapia de combinacion que comprende un inhibidor de tor cinasa y un analogo de citidina para tracar cancer. | |
BR112016004118A2 (pt) | uso de inibidores da acetil-coa carboxilase para tratamento de acne vulgar | |
SG10201810575WA (en) | Treatment of prostate cancer with tor kinase inhibitors | |
DOP2013000131A (es) | Composiciones y métodos para tratar el cáncer usando un inhibidor de pi3k y un inhibidor de mek | |
EP2558102A4 (en) | SYNERGISTIC INTERACTION OF AT LEAST ONE COMPONENT OF VITAMIN E AND TYROSINASE INHIBITORS FOR DERMATOLOGICAL APPLICATIONS | |
MX2018013715A (es) | Composiciones acuosas de capsaicinoides que comprenden un analgesico y un vehiculo acuoso, y uso de las mismas para el tratamiento del dolor. | |
WO2014071168A3 (en) | Administering inhibitors of tgfbeta signaling to improve muscle function in cancer patients | |
BR112019002945A2 (pt) | terapia de combinação para o tratamento de câncer pancreático | |
BR112012008951A2 (pt) | tratamento de neurotoxidez associada com combinações de 5-fu ou seus profármacos e inibidores de dpd | |
EA201491836A1 (ru) | Способы лечения рака с использованием ингибитора pi3k и ингибитора mek | |
Sebastian et al. | PARP Inhibition (OLAPARIB) Enhance Melphalan and Nutlin-3a Sensitivity in TP53 Positive Multiple Myeloma | |
NI201300052A (es) | Composiciones y métodos para tratar el cáncer usando un inhibidor de pi3k y un inhibidor de mek | |
CO6721062A2 (es) | Cmposiciones y métodos para tratar el cancer usando un inhibidor de pi3k y un inhibidor de mek |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |